• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.

作者信息

Huff-Hardy Kayci, Bedair Mai, Vazquez Rebecca, Burstein Ezra

机构信息

Departments of *Internal Medicine, and †Dermatology, UT Southwestern Medical Center, Dallas, Texas.

出版信息

Inflamm Bowel Dis. 2017 Oct;23(10):E49. doi: 10.1097/MIB.0000000000001232.

DOI:10.1097/MIB.0000000000001232
PMID:28858074
Abstract
摘要

相似文献

1
Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.维多珠单抗与优特克单抗联合治疗难治性克罗恩病的疗效
Inflamm Bowel Dis. 2017 Oct;23(10):E49. doi: 10.1097/MIB.0000000000001232.
2
The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.抗 TNF 药物和 vedolizumab 或 ustekinumab 均治疗无效的克罗恩病患者的结局。
Dig Liver Dis. 2020 Oct;52(10):1148-1155. doi: 10.1016/j.dld.2020.07.031. Epub 2020 Aug 20.
3
[Ustekinumab for the treatment of Crohn's disease -Indication of Ustekinumab according to efficacy and safety].[优特克单抗治疗克罗恩病——基于疗效和安全性的优特克单抗适应证]
Nihon Shokakibyo Gakkai Zasshi. 2019;116(3):216-223. doi: 10.11405/nisshoshi.116.216.
4
An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.优特克单抗与维多珠单抗治疗肿瘤坏死因子治疗失败的克罗恩病患者的间接比较
J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer-2017-0041. Epub 2017 Nov 8.
5
Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.
Acta Derm Venereol. 2017 Mar 10;97(3):389-390. doi: 10.2340/00015555-2544.
6
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.乌司奴单抗相较于维得利珠单抗在既往抗 TNF 治疗失败的克罗恩病患者中具有更优的有效性结局。
Aliment Pharmacol Ther. 2020 Jul;52(1):123-134. doi: 10.1111/apt.15745. Epub 2020 May 22.
7
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.130 例抗 TNF 治疗失败的克罗恩病患者中乌司奴单抗或维得利珠单抗治疗 1 年后的疗效比较。
Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352. doi: 10.1111/apt.16057. Epub 2020 Sep 10.
8
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitis.一线抗肿瘤坏死因子（TNF）药物优特克单抗和维得利珠单抗在克罗恩病中的表现相似，但在溃疡性结肠炎中并非如此。
Eur J Gastroenterol Hepatol. 2025 May 1;37(5):557-564. doi: 10.1097/MEG.0000000000002940. Epub 2025 Feb 6.
9
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.英夫利昔单抗和维得利珠单抗治疗炎症性肠病的治疗药物监测。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172. doi: 10.1093/ibd/izy134.
10
Is Ustekinumab the best treatment option in patients with Crohn's disease and coexistent multiple sclerosis?优特克单抗是克罗恩病合并多发性硬化症患者的最佳治疗选择吗？
Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):337.

引用本文的文献

1
Dual anti-cytokine biologic and/or targeted synthetic therapy combination in spondyloarthritis: a narrative review. Are we missing the opportunity for higher remission rates?脊柱关节炎中双重抗细胞因子生物制剂和/或靶向合成疗法联合应用：一项叙述性综述。我们是否错失了实现更高缓解率的机会？
Front Med (Lausanne). 2025 Jun 3;12:1576411. doi: 10.3389/fmed.2025.1576411. eCollection 2025.
2
Dual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.维多珠单抗和优特克单抗联合生物疗法可诱导难治性克罗恩病缓解。
Crohns Colitis 360. 2024 Dec 17;7(1):otae080. doi: 10.1093/crocol/otae080. eCollection 2025 Jan.
3
Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.
炎症性肠病双重生物疗法的进展：疗效、安全性及未来方向。
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241309871. doi: 10.1177/17562848241309871. eCollection 2025.
4
Combination treatment of inflammatory bowel disease: Present status and future perspectives.炎症性肠病的联合治疗：现状与未来展望。
World J Gastroenterol. 2024 Apr 21;30(15):2068-2080. doi: 10.3748/wjg.v30.i15.2068.
5
Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease.生物制剂与新型小分子药物联合用于炎症性肠病的先进治疗方案
Gastroenterol Hepatol (N Y). 2023 May;19(5):251-263.
6
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.双重生物疗法在炎症性肠病治疗中的新作用。
World J Clin Cases. 2023 Apr 26;11(12):2621-2630. doi: 10.12998/wjcc.v11.i12.2621.
7
Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study.中度至重度小儿炎症性肠病的双生物制剂疗法：一项回顾性研究
Children (Basel). 2022 Dec 21;10(1):11. doi: 10.3390/children10010011.
8
Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.双生物制剂疗法治疗儿童炎症性肠病：文献综述
J Clin Med. 2022 Apr 3;11(7):2004. doi: 10.3390/jcm11072004.
9
Unmet needs in inflammatory bowel disease.炎症性肠病中未满足的需求。
Curr Res Pharmacol Drug Discov. 2021 Nov 30;2:100070. doi: 10.1016/j.crphar.2021.100070. eCollection 2021.
10
Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.双重生物疗法治疗炎症性肠病患者的疗效与安全性：文献综述
Gastroenterol Hepatol (N Y). 2021 Sep;17(9):406-414.